- Home
- AORT
AORT
Artivion Inc.
as 03-28-2025 4:00pm EST
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | KENNESAW |
| Market Cap: | 1.0B | IPO Year: | 1993 |
| Target Price: | $31.40 | AVG Volume (30 days): | 504.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.36 - $32.33 | Next Earning Date: | 05-05-2025 |
| Revenue: | $388,537,000 | Revenue Growth: | 9.76% |
| Revenue Growth (this year): | 11.21% | Revenue Growth (next year): | 10.77% |
Stock Insider Trading Activity of Artivion Inc. (AORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Holloway Jean F | AORT | SVP, General Counsel | Mar 11 '25 | Sell | $23.61 | 18,020 | $425,509.86 | 197,184 | |
| Davis John E | AORT | Chief Commercial Officer | Mar 11 '25 | Sell | $23.61 | 15,100 | $356,548.75 | 208,778 | |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Mar 6 '25 | Sell | $24.80 | 1,603 | $39,761.13 | 115,880 | |
| Horton Amy | AORT | VP, Chief Accounting Officer | Mar 6 '25 | Sell | $24.80 | 1,048 | $25,995.01 | 146,651 | |
| Holloway Jean F | AORT | SVP, General Counsel | Mar 6 '25 | Sell | $24.80 | 2,124 | $52,685.40 | 197,184 | |
| Mackin James P | AORT | President & CEO | Mar 6 '25 | Sell | $24.78 | 88,439 | $2,190,848.33 | 865,283 | |
| Davis John E | AORT | Chief Commercial Officer | Mar 6 '25 | Sell | $24.80 | 2,618 | $64,938.70 | 208,778 | |
| Berry Lance A | AORT | Executive VP, CFO | Mar 6 '25 | Sell | $24.80 | 4,909 | $121,763.82 | 153,431 | |
| SEMEDO ANTHONY B. | AORT | Director | Mar 5 '25 | Buy | $25.29 | 2,100 | $53,140.50 | 600 | |
| Holloway Jean F | AORT | SVP, General Counsel | Mar 5 '25 | Sell | $25.29 | 472 | $11,934.52 | 197,184 |
Latest Artivion Inc. News
AORT Breaking Stock News: Dive into AORT Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
AORT: Raising target price to $26.00
Zacks
5 days ago
Do Options Traders Know Something About Artivion (AORT) Stock We Don't?
Argus Research
25 days ago
AORT: Lowering target price to $26.00
PR Newswire
25 days ago
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Simply Wall St.
25 days ago
Artivion Full Year 2024 Earnings: EPS Misses Expectations
Zacks
a month ago
Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround
Simply Wall St.
a month ago
Earnings Miss: Artivion, Inc. Missed EPS And Analysts Are Revising Their Forecasts
TipRanks
a month ago
Artivion price target lowered to $32 from $34 at Needham
Compare AORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AORT Artivion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.